drugset
drugset / Trial / NCT02576639

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639 ↗

Phase 2 Completed 124 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindBasic science

Summary

The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.

Timeline

Start
2015-08-10
Primary completion
2016-03-11
Completion
2016-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CNP520 Unknown 2 mg Oral
Subject CNP520 Unknown 10 mg Oral
Subject CNP520 Unknown 35 mg Oral
Subject CNP520 Unknown 85 mg Oral

Indications

Alzheimer disease